Outcomes of elacestrant in patients with ER-positive, HER2-negative, ESR1-mutated metastatic breast cancer who received prior endocrine therapy and cyclin-dependent kinase inhibitor in a real-world setting Authors: G. Curigliano, M. De Laurentiis, N. Harbeck, S. Kuemmel, J.Á. García-Sáenz, R. Sanchez Bayona, D. Rea, A. Okines, B. Pistilli, E. Sears, J. Maitland, S. Kloss, T. Wasserman, M. Ignatiadis Published: 2026 ABSTRACT BackgroundReal-world data analyses show durable benefits with elacestrant, with or without prior treatment with cyclin-dependent kinase 4/6 inhibitor (CDK4/6i). This cohort focused on patients with ER-positive/HER2-negative estrogen receptor 1 (ESR1)-mutated metastatic breast cancer (mBC) treated with elacestrant after at least one line of endocrine therapy (ET) combined with CDK4/6i (N = 281).Patients and methodsClaims data from the Komodo Research Dataset linked with Foundation Medicine clinical-genomics data were used. Primary outcome was median time-to-next-treatment (mTTNT).ResultsIn patients with ER-positive/HER2-negative ESR1-mutated mBC who received one to two prior lines of ET + CDK4/6i (n = 108), mTTNT with elacestrant was 8.2 months [95% confidence interval (CI) 6.0-12.2]. In patients who received one to two prior lines of ET + CDK4/6i for ≥12 months (n = 85), mTTNT was 9.0 months (95% CI 7.7-13.7), including an mTTNT of 12.2 months (95% CI 9.0-not reached) in those who received one prior line of ET (n = 31). In patients with liver and/or lung metastasis (n = 169), mTTNT was 6.9 months (95% CI 5.8-8.3), whereas it was 7.4 months (95% CI 5.6-12.9) in patients with brain metastasis (n = 68). In patients with coexisting ESR1- and phosphoinositide 3-kinase-pathway-mutated tumors (n = 115), mTTNT was 6.1 months (95% CI 5.0-8.1).ConclusionsElacestrant showed durable benefits in patients with ER-positive/HER2-negative ESR1-mutated mBC previously exposed to at least one line of ET + CDK4/6i, reinforcing the role of elacestrant as a potential first-choice option for patients with endocrine-sensitive tumors. Introduction Endocrine therapy (ET) plus a cyclin-dependent kinase 4/6 inhibitor (CDK4/6i) is the first-line standard-of-care (SOC) treatment for patients with estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer (mBC).1, 2, 3 Disease progression in these patients is associated with mechanisms of resistance, affecting the efficacy of subsequent therapy.4 Mutations in the estrogen receptor 1 (ESR1) gene are a common mechanism of acquired resistance that emerges in 40% to 50% of patients during ET at mBC progression.5,6 As such, testing for ESR1 mutations is recommended at each stage of disease progression in the metastatic setting.1, 2, 3 Results from the phase III EMERALD trial led to the approval of elacestrant (345 mg once daily) as the first oral selective ER degrader for the treatment of postmenopausal women and men with ER-positive/HER2-negative ESR1-mutated advanced or mBC with disease progression after at least one line of ET, including a CDK4/6i.7, 8, 9 In EMERALD, elacestrant was associated with a 45% reduction in risk of progression or death compared with SOC ET in patients with ER-positive/HER2-negative mBC who had ESR1-mutated tumors [median progression-free survival (mPFS), 3.8 compared with 1.9 months; hazard ratio (HR) 0.55, 95% confidence interval (CI) 0.39-0.77, P = 0.0005].9 An early decline in the Kaplan–Meier progression-free survival (PFS) curves for both arms revealed possible ET resistance in some patients, followed by clear separation of the survival curves, suggesting treatment benefit favoring elacestrant in patients with more endocrine-sensitive tumors and ER-driven disease.9 Although EMERALD allowed patients with primary endocrine resistance, the majority of patients treated in the first-line setting received at least 1 year of prior ET + CDK4/6i; therefore, outcomes by prior duration of ET + CDK4/6i were evaluated in exploratory subgroup analyses.10 In patients with ESR1-mutated tumors who received prior ET + CDK4/6i for at least 12 months, the mPFS for elacestrant compared with SOC ET was 8.6 compared with 1.9 months (HR 0.41, 95% CI 0.26-0.63).10 A clinically meaningful improvement in PFS for elacestrant compared with SOC ET was also consistent across relevant subgroups, suggesting that elacestrant may enable ET sequencing in the second-line setting before other targeted therapies and drug combinations, potentially delaying the need for chemotherapy or antibody–drug conjugate-based regimens.10 Recent real-world studies using US health care insurance claims data from two distinct clinical-genomic datasets evaluated the use of single-agent elacestrant in ER-positive/HER2-negative ESR1-mutated mBC, providing further evidence supporting findings from the EMERALD subgroup analyses.11,12 Both datasets evaluated outcomes using time-to-next-treatment (TTNT), a real-world endpoint that complements PFS by reflecting treatment benefit duration in the context of clinical decision making, and according to some publications, TTNT may serve as a surrogate for PFS.11, 12, 13, 14, 15 In an independent study using the GuardantINFORM dataset (N = 756), 76% of patients (n = 573) received prior CDK4/6i for mBC; among the subset of patients (n = 203) who received no more than one prior line of ET ± CDK4/6i, the median time-to-next-treatment (mTTNT) was 8.8 months (duration of prior CDK4/6i exposure was unknown at time of analysis).11 Similarly, in a different study using the Komodo Research Dataset (KRD) linked to Foundation Medicine clinical-genomics (FMICG) data (N = 306), 94% of patients (n = 287) received prior ET ± CDK4/6i for at least 12 months; for those who received one to two prior lines of ET (n = 116), the mTTNT was 8.4 months.12 After the US Food and Drug Administration-approved indication of elacestrant, both analyses included patients who received ET with or without CDK4/6i therapy in the metastatic setting.7 Elacestrant was associated with a longer mTTNT in these real-world analyses than the mPFS reported in EMERALD, particularly among patients who received elacestrant in earlier lines of therapy.12 Notably, in patients with coexisting ESR1 and phosphoinositide 3-kinase (PI3K) pathway-mutated tumors [phosphatidylinositol-3-kinase catalytic subunit alpha (PIK3CA)/protein kinase B (AKT)/phosphatase and tensin homolog (PTEN)], both real-world analyses suggest that elacestrant retains antitumor activity with clinically meaningful mTTNTs of 6.3 months (n = 130)11 and 5.2 months (n = 234),12 which are consistent with findings from the EMERALD subgroup analysis that showed an mPFS of 5.5 months (n = 27).10 These findings, together with data from other clinical trials and independent real-world analyses, suggest that the ER pathway may remain the primary driver of disease after progression on ET ± CDK4/6i therapy in the metastatic setting.16, 17, 18, 19, 20, 21, 22 To further characterize real-world outcomes of elacestrant in the context of the European Medicines Agency-approved indication,8 this retrospective study specifically evaluated the use of elacestrant in patients with ER-positive/HER2-negative mBC and ESR1-mutated tumors after at least one line of ET + CDK4/6i. Patients and methods US health care insurance claims data from the KRD, linked with FMICG data, were used to conduct this cohort study. The KRD provides comprehensive US census-level representation of a large and diverse patient cohort across all ages, income levels, races, and ethnicities, ensuring socioeconomic diversity by sourcing claims from commercial, Medicare, Medicare Advantage, Medicaid, Managed Medicaid, and other payers and is generally representative of the demographics and treatment exposures of patients with breast cancer across the US. Variables within KRD include inpatient and outpatient diagnoses and procedures, provider information, payer type, mortality data, race, and ethnicity data. The deidentified KRD and FMICG databases adhere to Article 164.514(a)-(h)1ii of the US Health Insurance Portability and Accountability Act. Institutional review board exemption and patient consent were not required. Patients with ER-positive/HER2-negative ESR1-mutated mBC who had received at least one prior line of ET + CDK4/6i and were treated with elacestrant between January 2023 and November 2025 were included. The index date was defined as the time of first elacestrant fill. Demographic information at index date included clinical and genomic characteristics identified during the baseline period, which spanned at least 6 months before the index date and included all available data. The first-line setting was considered the first mBC treatment regimen observed; mBC treatments initiated within 30 days of regimen initiation were considered part of the same line of therapy. Subsequent treatment lines were based on initiation of a new drug more than 30 days after regimen initiation. Real-world TTNT was defined as the time from index date until initiation of a new line of treatment; mTTNT was estimated using the Kaplan–Meier method. Follow-up time for patients without an event was censored at death, end of clinical activity, end of data availability, or at elacestrant discontinuation, defined as at least a 90-day gap from the end of elacestrant days of supply, whichever occurred first. Safety data were not available through this claims-based dataset, although TTNT partially reflects time course of treatment tolerability and patient compliance.14 Genomic data were sourced from FMICG (Foundation Medicine; RRID:SCR_025628), which were generated using the FoundationOne assay. Mutational data included status of ESR1 mutations (D538G, Y537S/Y537N/Y537C, or E380Q), PIK3CA mutations (H1047R/H1047L/H1047Q/H1047I/H1047Y, E545K/E545G/E545A/E545Q, or E542K), AKT alterations, and PTEN loss of function from tissue and plasma samples in patients within the KRD who had received elacestrant and had an eligible line of treatment defined as initiation of a new drug at least 30 days after the last fill. Results Patients Within the clinical-genomic dataset, 281 patients were identified with ER-positive/HER2-negative ESR1-mutated mBC and who had received at least one prior line of ET + CDK4/6i. Patient demographics, including clinical and genomic characteristics, are summarized in Table 1. Among all patients, 90.4% had visceral metastasis, 43.4% had liver metastasis, 31.0% had lung metastasis, 24.2% had brain and spinal cord metastasis, and only 7.8% had bone-only metastasis. Prior treatments for mBC included fulvestrant (71.2%) and chemotherapy (43.4%). The most common ESR1 mutation allelic variants were Y537S, Y537N, or Y537C (49.1%) and D538G (47.3%). Most patients had one ESR1 variant (79.0%). Coexisting PIK3CA mutations were detected in 43.1% of patients.Table 1Demographics and clinical and genomic characteristicsParametersN = 281Median age (years) as of elacestrant initiation65.3Female, n (%)277 (98.6)Race/ethnicity, n (%) White (non-Hispanic)175 (62.3) Black or African American37 (13.2) Hispanic or Latino20 (7.1) Asian or Pacific Islander14 (5.0) Other11 (3.9) Unknown6 (2.1) Missing18 (6.4)Insurance type, n (%) Medicare175 (62.3) Commercial75 (26.7) Medicaid26 (9.3) Missing5 (1.8)Metastatic sites, n (%) Visceral metastasis254 (90.4) Liver122 (43.4) Lung87 (31.0) Brain and spinal cord68 (24.2) Bone/lymph node metastatic site only24 (8.5) Bone22 (7.8) Missing3 (1.1)Prior mBC treatment use, n (%) ET + CDK4/6i281 (100) 1-2 prior lines108 (38.4) 1 prior line34 (12.1) 2 prior lines74 (26.3) ≥3 prior lines173 (61.6) ET + CDK4/6i ≥12 months210 (74.7) Fulvestrant200 (71.2) Chemotherapy122 (43.4) Alpelisib and ET33 (11.7) Capivasertib and ET10 (3.6)Genomic alterations, n (%) ESR1 mutations281 (100) Y537 (S/N/C) variants138 (49.1) D538G variant133 (47.3) E380Q variant27 (9.6) Number of ESR1 mutation variants 1222 (79.0) ≥259 (21.0) PIK3CA mutationsa121 (43.1) H1047R variant40 (14.2) E542K variant17 (6.0) E545K variant29 (10.3) Other35 (12.5) PTEN loss20 (7.1) AKT alteration12 (4.3)AKT, protein kinase B; CDK4/6i, cyclin-dependent kinase 4 and 6 inhibitor; ESR1, estrogen receptor 1; ET, endocrine therapy; mBC, metastatic breast cancer; PIK3CA, phosphatidylinositol-3-kinase catalytic subunit alpha; PTEN, phosphatase and tensin homolog.aVariants of clinical interest are listed. Table 1Demographics and clinical and genomic characteristicsParametersN = 281Median age (years) as of elacestrant initiation65.3Female, n (%)277 (98.6)Race/ethnicity, n (%) White (non-Hispanic)175 (62.3) Black or African American37 (13.2) Hispanic or Latino20 (7.1) Asian or Pacific Islander14 (5.0) Other11 (3.9) Unknown6 (2.1) Missing18 (6.4)Insurance type, n (%) Medicare175 (62.3) Commercial75 (26.7) Medicaid26 (9.3) Missing5 (1.8)Metastatic sites, n (%) Visceral metastasis254 (90.4) Liver122 (43.4) Lung87 (31.0) Brain and spinal cord68 (24.2) Bone/lymph node metastatic site only24 (8.5) Bone22 (7.8) Missing3 (1.1)Prior mBC treatment use, n (%) ET + CDK4/6i281 (100) 1-2 prior lines108 (38.4) 1 prior line34 (12.1) 2 prior lines74 (26.3) ≥3 prior lines173 (61.6) ET + CDK4/6i ≥12 months210 (74.7) Fulvestrant200 (71.2) Chemotherapy122 (43.4) Alpelisib and ET33 (11.7) Capivasertib and ET10 (3.6)Genomic alterations, n (%) ESR1 mutations281 (100) Y537 (S/N/C) variants138 (49.1) D538G variant133 (47.3) E380Q variant27 (9.6) Number of ESR1 mutation variants 1222 (79.0) ≥259 (21.0) PIK3CA mutationsa121 (43.1) H1047R variant40 (14.2) E542K variant17 (6.0) E545K variant29 (10.3) Other35 (12.5) PTEN loss20 (7.1) AKT alteration12 (4.3)AKT, protein kinase B; CDK4/6i, cyclin-dependent kinase 4 and 6 inhibitor; ESR1, estrogen receptor 1; ET, endocrine therapy; mBC, metastatic breast cancer; PIK3CA, phosphatidylinositol-3-kinase catalytic subunit alpha; PTEN, phosphatase and tensin homolog.aVariants of clinical interest are listed. Demographics and clinical and genomic characteristics AKT, protein kinase B; CDK4/6i, cyclin-dependent kinase 4 and 6 inhibitor; ESR1, estrogen receptor 1; ET, endocrine therapy; mBC, metastatic breast cancer; PIK3CA, phosphatidylinositol-3-kinase catalytic subunit alpha; PTEN, phosphatase and tensin homolog. Variants of clinical interest are listed. Outcomes In the 281 patients analyzed, the mTTNT with elacestrant was 7.4 months (95% CI 6.2-8.3), with a median follow-up time of 9.6 months (Table 2). Elacestrant outcomes were evaluated by prior lines of ET received in the metastatic setting. The mTTNT in patients who received one to two prior lines of ET + CDK4/6i (n = 108) was 8.2 months (95% CI 6.0-12.2). In those patients who received one to two prior lines of ET + CDK4/6i for at least 12 months (n = 85), mTTNT was 9.0 months (95% CI 7.7-13.7). Within this population who received a longer duration of prior CDK4/6i exposure (≥12 months), the mTTNT in patients who received one prior line of ET (n = 31) was 12.2 months [95% CI 9.0-not reached (NR)] and 8.2 months (95% CI 5.5-13.7) in those who received two prior lines of ET (n = 54). The mTTNT in patients who received three or more prior lines of ET + CDK4/6i was 7.1 months (95% CI 6.1-8.1). This improvement of durable benefit in patients with one prior line of ET compared with two prior lines of ET is consistent with what was observed in other real-world evidence publications.11,12Table 2mTTNT benefit in relevant subgroupsPatient subgroupN (%)No. of events (%)mTTNT, months (95% CI)≥1 prior line of ET + CDK4/6i281 (100)157 (55.9)7.4 (6.2-8.3)1-2 prior lines of treatment108 (38.4)56 (51.9)8.2 (6.0-12.2) 1-2 prior lines of treatment ≥12 months85 (30.2)39 (45.9)9.0 (7.7-13.7) 1 prior line of treatment ≥12 months31 (11.0)12 (38.7)12.2 (9.0-NR) 2 prior lines of treatment ≥12 months54 (19.2)27 (50.0)8.2 (5.5-13.7)≥3 prior lines of treatment173 (61.6)101 (58.4)7.1 (6.1-8.1)Liver and/or lung metastasis169 (60.1)95 (56.2)6.9 (5.8-8.3) Liver metastasisa122 (43.4)71 (58.2)6.5 (5.8-8.3) Lung metastasisa87 (31.0)47 (54.0)7.7 (5.8-12.2)Lung and/or bone metastasis255 (90.7)141 (55.3)7.4 (6.3-8.3)No liver metastasisb159 (56.6)86 (54.1)7.7 (6.2-10.3)Brain metastasis68 (24.2)37 (54.4)7.4 (5.6-12.9)No prior chemotherapy159 (56.6)81 (50.9)8.0 (6.4-9.9)Prior chemotherapy122 (43.4)76 (62.3)6.5 (5.3-7.9)No prior fulvestrant81 (28.8)41 (50.6)7.7 (5.8-20.0)Prior fulvestrant200 (71.2)116 (58.0)7.1 (6.1-8.2)PIK3CA wild-type160 (56.9)80 (50.0)8.3 (7.1-12.9)Coexisting ESR1 and PI3K pathway mutationsc115 (40.9)74 (64.3)6.1 (5.0-8.1)ESR1 Y537S and/or Y537N and/or Y537C mutations138 (49.1)80 (58.0)6.4 (5.3-8.1)ESR1 D538G mutation133 (47.3)69 (51.9)8.0 (6.3-13.1)ESR1 E380Q mutation27 (9.6)14 (51.9)7.8 (4.8-NR)Bold values highlight the primary endpoint (mTTNT) results.AKT, protein kinase B; CDK4/6i, cyclin-dependent kinase 4/6 inhibitor; CI, confidence interval; ESR1, estrogen receptor 1; ET, endocrine therapy; NR, not reached; PI3K, phosphoinositide 3-kinase; PIK3CA, phosphatidylinositol-3-kinase catalytic subunit alpha; PTEN, phosphatase and tensin homolog; mTTNT, median time-to-next-treatment.aPatients with liver and lung disease were counted twice in each category.bAny metastatic site except for liver.cIncludes patients with at least one ESR1 mutation variant (Y537C and/or Y537N and/or Y537S and/or D538G and/or E380Q) and at least one PIK3CA mutation variant (H1047 and/or E545 and/or E542), PTEN loss of function, or an AKT mutation (AKT1, AKT2, or AKT3 mutation). Table 2mTTNT benefit in relevant subgroupsPatient subgroupN (%)No. of events (%)mTTNT, months (95% CI)≥1 prior line of ET + CDK4/6i281 (100)157 (55.9)7.4 (6.2-8.3)1-2 prior lines of treatment108 (38.4)56 (51.9)8.2 (6.0-12.2) 1-2 prior lines of treatment ≥12 months85 (30.2)39 (45.9)9.0 (7.7-13.7) 1 prior line of treatment ≥12 months31 (11.0)12 (38.7)12.2 (9.0-NR) 2 prior lines of treatment ≥12 months54 (19.2)27 (50.0)8.2 (5.5-13.7)≥3 prior lines of treatment173 (61.6)101 (58.4)7.1 (6.1-8.1)Liver and/or lung metastasis169 (60.1)95 (56.2)6.9 (5.8-8.3) Liver metastasisa122 (43.4)71 (58.2)6.5 (5.8-8.3) Lung metastasisa87 (31.0)47 (54.0)7.7 (5.8-12.2)Lung and/or bone metastasis255 (90.7)141 (55.3)7.4 (6.3-8.3)No liver metastasisb159 (56.6)86 (54.1)7.7 (6.2-10.3)Brain metastasis68 (24.2)37 (54.4)7.4 (5.6-12.9)No prior chemotherapy159 (56.6)81 (50.9)8.0 (6.4-9.9)Prior chemotherapy122 (43.4)76 (62.3)6.5 (5.3-7.9)No prior fulvestrant81 (28.8)41 (50.6)7.7 (5.8-20.0)Prior fulvestrant200 (71.2)116 (58.0)7.1 (6.1-8.2)PIK3CA wild-type160 (56.9)80 (50.0)8.3 (7.1-12.9)Coexisting ESR1 and PI3K pathway mutationsc115 (40.9)74 (64.3)6.1 (5.0-8.1)ESR1 Y537S and/or Y537N and/or Y537C mutations138 (49.1)80 (58.0)6.4 (5.3-8.1)ESR1 D538G mutation133 (47.3)69 (51.9)8.0 (6.3-13.1)ESR1 E380Q mutation27 (9.6)14 (51.9)7.8 (4.8-NR)Bold values highlight the primary endpoint (mTTNT) results.AKT, protein kinase B; CDK4/6i, cyclin-dependent kinase 4/6 inhibitor; CI, confidence interval; ESR1, estrogen receptor 1; ET, endocrine therapy; NR, not reached; PI3K, phosphoinositide 3-kinase; PIK3CA, phosphatidylinositol-3-kinase catalytic subunit alpha; PTEN, phosphatase and tensin homolog; mTTNT, median time-to-next-treatment.aPatients with liver and lung disease were counted twice in each category.bAny metastatic site except for liver.cIncludes patients with at least one ESR1 mutation variant (Y537C and/or Y537N and/or Y537S and/or D538G and/or E380Q) and at least one PIK3CA mutation variant (H1047 and/or E545 and/or E542), PTEN loss of function, or an AKT mutation (AKT1, AKT2, or AKT3 mutation). mTTNT benefit in relevant subgroups Bold values highlight the primary endpoint (mTTNT) results. AKT, protein kinase B; CDK4/6i, cyclin-dependent kinase 4/6 inhibitor; CI, confidence interval; ESR1, estrogen receptor 1; ET, endocrine therapy; NR, not reached; PI3K, phosphoinositide 3-kinase; PIK3CA, phosphatidylinositol-3-kinase catalytic subunit alpha; PTEN, phosphatase and tensin homolog; mTTNT, median time-to-next-treatment. Patients with liver and lung disease were counted twice in each category. Any metastatic site except for liver. Includes patients with at least one ESR1 mutation variant (Y537C and/or Y537N and/or Y537S and/or D538G and/or E380Q) and at least one PIK3CA mutation variant (H1047 and/or E545 and/or E542), PTEN loss of function, or an AKT mutation (AKT1, AKT2, or AKT3 mutation). Across clinically relevant subgroups, the mTTNT in patients with liver and/or lung metastasis (n = 169) was 6.9 months (95% CI 5.8-8.3; Table 2). Among those with liver metastasis (n = 122), mTTNT was 6.5 months (95% CI 5.8-8.3) and patients with lung metastasis (n = 87) had an mTTNT of 7.7 months (95% CI 5.8-12.2). Patients with lung and/or bone metastasis had an mTTNT of 7.4 months (95% CI 6.3-8.3) and those without liver metastasis had an mTTNT of 7.7 months (95% CI 6.2-10.3). In patients with brain metastasis (n = 68), the mTTNT was 7.4 months (95% CI 5.6-12.9). Outcomes were analyzed by exposure to prior treatments in the metastatic setting. In patients with no prior chemotherapy (n = 159), the mTTNT was 8.0 months (95% CI 6.4-9.9), whereas in patients with prior chemotherapy (n = 122), the mTTNT was 6.5 months (95% CI 5.3-7.9). The mTTNT was 7.7 months (95% CI 5.8-20.0) in those with no prior fulvestrant (n = 81), whereas in those who received prior fulvestrant (n = 200), the mTTNT was 7.1 months (95% CI 6.1-8.2). Outcomes were also analyzed based on the available genomic data (Table 2). The mTTNT was 6.4 months (95% CI 5.3-8.1) in patients with ESR1 mutation variants Y537S/Y537N/Y537C (n = 138) and 8.0 months (95% CI 6.3-13.1) in patients with ESR1 mutation variant D538G (n = 133). In patients with ESR1 mutation variant E380Q, the mTTNT was 7.8 months (95% CI 4.8-NR). In patients with coexisting ESR1- and PI3K pathway-mutated (PIK3CA/AKT/PTEN) tumors (n = 115), the mTTNT was 6.1 months (95% CI 5.0-8.1). In patients with PIK3CA wild-type tumors, elacestrant mTTNT was 8.3 months (95% CI 7.1-12.9). Kaplan–Meier PFS curves for the different subgroups are available in Supplementary Figures S1-S4 (available at https://doi.org/10.1016/j.esmoop.2026.108535). Discussion This real-world study provides further insights into patients with ER-positive/HER2-negative ESR1-mutated mBC treated with elacestrant who received at least one prior line of ET + CDK4/6i. The mTTNT in patients who received one to two prior lines of ET + CDK4/6i was 8.2 months. As most patients in real-world clinical practice receive ET + CDK4/6i at least 12 months before initiating elacestrant,23 our analysis evaluated outcomes in similar subgroups. In a large-scale real-world cohort, elacestrant showed durable efficacy, particularly in those with prolonged prior ET exposure. In patients who received one to two prior lines of ET + CDK4/6i for at least 12 months, the mTTNT was 9.0 months. A longer mTTNT of 12.2 months was observed in patients with one prior line of ET + CDK4/6i for at least 12 months compared with 8.2 months in those patients who received two prior lines of ET + CDK4/6i for at least 12 months. These findings closely align with the subgroup analysis from EMERALD, in which elacestrant was associated with an mPFS of 8.6 months in patients with one to two prior lines of ET + CDK4/6i for at least 12 months in those with ESR1-mutated tumors (Table 3).10Table 3Elacestrant analyses in patients with prior ET plus cyclin-dependent kinase 4/6 inhibitorPopulation and outcomesReal-world KRD/FMICG studyPhase III EMERALD subgroup analyses10Patient populationn (%)n(%)Total patients28178Prior ET + CDK4/6i for mBC281 (100)78 (100) Prior ET + CDK4/6i ≥12 months210 (75)78 (100)Patients with visceral metastasis254 (90)58 (74)Prior fulvestrant for mBC200 (71)13 (17)Prior chemotherapy for mBC122 (43)16 (21)Coexisting ESR1 and PI3K pathway mutationsa,b115 (41)27 (35)Median efficacy outcomes, monthsnmTTNTnmPFS 1-2 prior lines of treatment ≥12 months859.0788.6 Visceral (liver and/or lung) metastasis169a6.9567.3 Coexisting ESR1 and PI3K pathway mutationsb,c115a6.1275.5 PIK3CA wild-type160a8.3519.0AKT, protein kinase B; CDK4/6i, cyclin-dependent kinase 4/6 inhibitor; ESR1, estrogen receptor 1; ET, endocrine therapy; FMICG, Foundation Medicine clinical-genomics; KRD, Komodo Research Dataset; mBC, metastatic breast cancer; mPFS, median progression-free survival; mTTNT, median time-to-next-treatment; PI3K, phosphoinositide 3-kinase; PIK3CA, phosphatidylinositol-3-kinase catalytic subunit alpha; PTEN, phosphatase and tensin homolog.aIncludes patients who received <12 months prior ET + CDK4/6i.bIncludes patients with ESR1 mutation variants (Y537C and/or Y537N and/or Y537S and/or D538G and/or E380Q) and PIK3CA mutation variants (H1047 and/or E545 and/or E542), AKT alteration, or PTEN loss of function.cEMERALD subgroup analysis includes patients with ESR1- and PIK3CA-mutated tumors. Table 3Elacestrant analyses in patients with prior ET plus cyclin-dependent kinase 4/6 inhibitorPopulation and outcomesReal-world KRD/FMICG studyPhase III EMERALD subgroup analyses10Patient populationn (%)n(%)Total patients28178Prior ET + CDK4/6i for mBC281 (100)78 (100) Prior ET + CDK4/6i ≥12 months210 (75)78 (100)Patients with visceral metastasis254 (90)58 (74)Prior fulvestrant for mBC200 (71)13 (17)Prior chemotherapy for mBC122 (43)16 (21)Coexisting ESR1 and PI3K pathway mutationsa,b115 (41)27 (35)Median efficacy outcomes, monthsnmTTNTnmPFS 1-2 prior lines of treatment ≥12 months859.0788.6 Visceral (liver and/or lung) metastasis169a6.9567.3 Coexisting ESR1 and PI3K pathway mutationsb,c115a6.1275.5 PIK3CA wild-type160a8.3519.0AKT, protein kinase B; CDK4/6i, cyclin-dependent kinase 4/6 inhibitor; ESR1, estrogen receptor 1; ET, endocrine therapy; FMICG, Foundation Medicine clinical-genomics; KRD, Komodo Research Dataset; mBC, metastatic breast cancer; mPFS, median progression-free survival; mTTNT, median time-to-next-treatment; PI3K, phosphoinositide 3-kinase; PIK3CA, phosphatidylinositol-3-kinase catalytic subunit alpha; PTEN, phosphatase and tensin homolog.aIncludes patients who received <12 months prior ET + CDK4/6i.bIncludes patients with ESR1 mutation variants (Y537C and/or Y537N and/or Y537S and/or D538G and/or E380Q) and PIK3CA mutation variants (H1047 and/or E545 and/or E542), AKT alteration, or PTEN loss of function.cEMERALD subgroup analysis includes patients with ESR1- and PIK3CA-mutated tumors. Elacestrant analyses in patients with prior ET plus cyclin-dependent kinase 4/6 inhibitor AKT, protein kinase B; CDK4/6i, cyclin-dependent kinase 4/6 inhibitor; ESR1, estrogen receptor 1; ET, endocrine therapy; FMICG, Foundation Medicine clinical-genomics; KRD, Komodo Research Dataset; mBC, metastatic breast cancer; mPFS, median progression-free survival; mTTNT, median time-to-next-treatment; PI3K, phosphoinositide 3-kinase; PIK3CA, phosphatidylinositol-3-kinase catalytic subunit alpha; PTEN, phosphatase and tensin homolog. Includes patients who received <12 months prior ET + CDK4/6i. Includes patients with ESR1 mutation variants (Y537C and/or Y537N and/or Y537S and/or D538G and/or E380Q) and PIK3CA mutation variants (H1047 and/or E545 and/or E542), AKT alteration, or PTEN loss of function. EMERALD subgroup analysis includes patients with ESR1- and PIK3CA-mutated tumors. Among other subgroups, patients with visceral (liver and/or lung) metastasis had an mTTNT benefit of 6.9 months, similar to the mPFS of 7.3 months reported for elacestrant in the EMERALD subgroup analysis (Table 3).10 In patients with liver metastasis, the mTTNT was 6.5 months. In patients without liver metastasis, mTTNT was 7.7 months. Patients with no prior exposure to chemotherapy or fulvestrant trended toward a higher TTNT with elacestrant relative to those with prior chemotherapy (mTTNT, 8.0 compared with 6.5 months, respectively) or fulvestrant (mTTNT, 7.7 compared with 7.1 months, respectively). Genomic findings from our analysis in patients with coexisting ESR1- and PI3K pathway-mutated tumors after at least one line of prior ET + CDK4/6i showed an mTTNT of 6.1 months. This outcome is consistent with the 5.5-month mPFS observed in the subgroup of patients with coexisting ESR1- and PIK3CA-mutated tumors who received prior ET + CDK4/6i for at least 12 months in EMERALD (Table 3).10 Data from the CAPItello-291 trial indicated that patients with AKT pathway-altered tumors previously treated with CDK4/6i reached an mPFS of 5.5 months using capivasertib plus fulvestrant.18,19 In the FINER trial, the use of ipatasertib and fulvestrant in the PI3K/AKT/PTEN-altered population also showed 5.5 months of mPFS.20 However, the FINER trial saw a lower mPFS of 3.7 months in ESR1-mutated cases. Due to the retrospective, observational design of real-world analyses, only associations between treatments and outcomes can be inferred rather than causality. Limitations include challenges in interpreting clinical and surrogate outcomes, gaps in data completeness, variable definitions of treatment lines, descriptions of specific timing and modality of genomic testing, interpretations of treatment sequencing after multiple lines of treatment, and complexities surrounding censoring and observation periods. TTNT is widely recognized as a well-established, reliable, and objective real-world endpoint that complements PFS, as it reflects duration of disease control, treatment tolerability, and patient compliance; however, it carries distinct clinical implications and may be affected by factors unrelated to disease progression.13, 14, 15 Conclusion These findings highlight the importance of personalized therapy selection and testing for ESR1 mutations at each metastatic disease progression (if not detected previously). Outcomes from this study provide additional evidence that elacestrant provides a durable benefit in patients with ER-positive/HER2-negative mBC and ESR1-mutated tumors after at least one line of ET + CDK4/6i, reinforcing the role of elacestrant as a potential first-choice option for patients with endocrine-sensitive tumors.